MP52-15 ANDROGEN DEPRIVATION THERAPY AND SUBSEQUENT HEMATOLOGIC DISORDERS IN 17,168 PATIENTS WITH PROSTATE CANCER

Abstract

You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) III1 Apr 2018MP52-15 ANDROGEN DEPRIVATION THERAPY AND SUBSEQUENT HEMATOLOGIC DISORDERS IN 17,168 PATIENTS WITH PROSTATE CANCER Jui-Ming Liu, Heng-Chang Chuang, Chun-Te Wu, Yu-Li Su, and Ren-Jun Hsu Jui-Ming LiuJui-Ming Liu More articles by this author , Heng-Chang ChuangHeng-Chang Chuang More articles by this author , Chun-Te WuChun-Te Wu More articles by this author , Yu-Li SuYu-Li Su More articles by this author , and Ren-Jun HsuRen-Jun Hsu More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.1666AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Androgen deprivation therapy (ADT) has been the mainstay treatment for advanced prostate cancer (PCa). Various ADT adverse effects have been reported. However, studies in subsequent hematologic disorders of ADT were limited. METHODS A population-based nationwide cohort study of 17,168 patients newly diagnosed with PCa between 1996 and 2013 was identified from the Taiwan National Health Insurance Research Database. According to different therapeutic approaches, patients were classified as receiving ADT, radiotherapy(RT), and radical prostatectomy(RP). Study outcomes were hematologic disorders including anemia and hematologic malignancies. We used propensity score–matched analysis, Cox proportional hazards models, and Kaplan-Meier curves to investigate the risk of subsequent hematologic disorders of ADT. RESULTS Of the 17,168 selected patients with PCa, 13,318 patients were met all inclusion and exclusion criteria, with 8,122 receiving ADT, 1,797 receiving RT, and 3,399 receiving RP, respectively. After propensity score matching, there were 1,797 ADT users, 1,797 receiving RT, and 1,797 receiving RP in the study cohort with a mean follow-up period of 5.36 years. Compared to patients with RP, ADT group and RT group were statistically increased risk of subsequent hematologic disorders (ADT: adjusted hazard ratio (aHR) 1.71, 95%CI 1.41-2.08; RT: aHR 2.08,95%CI 1.71-2.51) after Cox proportional hazards models (Table 1). Kaplan-Meier curves with higher to lower cumulative probability of remaining hematologic disorders–free were RP , ADT without bone metastasis, RT, and ADT with bone metastasis (Figure 1). CONCLUSIONS ADT use in patients with PCa may increase the risk of subsequent hematologic disorders. Further studies are warranted to investigate between ADT and hematologic disorders. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e700-e701 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Jui-Ming Liu More articles by this author Heng-Chang Chuang More articles by this author Chun-Te Wu More articles by this author Yu-Li Su More articles by this author Ren-Jun Hsu More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...